SecBot SecBot

PSNL

Personalis, Inc.
Nasdaq· Services-Medical Laboratories· Inc. DE· CIK 0001527753 Healthcare & Medical Devices
$14.80 −0.91 (−5.79%)
Nov 16 4:00 PM ET · prev $15.71
Market cap
$1.7B
Small cap
Consensus
Buy
55% Buy or better · 11 analysts
Median target
$16.25
+10% · range $13.00–16.25
1 year
+97.9%
from $7.48 · Nov 17
30 days
−6.8%
from $15.88
52-week range
$5.04–18.38
−19% from high · low Apr 29
Avg volume 20D
2.33M
Nov 16 spike 6.32M
Short interest
6.75M
≈6.2% of shares · −0.7%
Days to cover
3.3
at average volume
Insider net
−$7.8M
0 buyers · 4 sellers · since Feb 23
New fund stakes
2
Q3 2026 13F · 0 exits
Filing reports
29
analyzed by SecBot
SecBot read MIXED 15 reports · 90 days
Balance 1 bearish · 2 bullish · 12 neutral oldest → newest, height = score
Avg score ·High conf. 12/15

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    4 insiders sold $7.8M.

  • InstitutionsBULLISH

    Q3 2026: 27 added (2 new), 17 trimmed or exited. Largest new: Sculptor Capital $14.7M.

  • AnalystsBULLISH

    6 of 11 rate it Buy or better. Median target $16.25 (+10%).

  • EstimatesFLAT

    Current-quarter EPS estimate −$0.237 → −$0.233 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest −0.7% to 6.75M shares. 3.3 days to cover, ≈6.2% of shares.

  • TrendDOWNTREND

    8% below its 50-day average.

Who's buying

13F· Q3 2026
2
new positions
0
exits
$14.7M
in new stakes · top 1 shown
FundMoveSharesValue
Aberdeen Group plcADD5,211,939$148.6M
Qube Research & Technologies LtdDOUBLED2,184,756$35.6M
Nuveen, LLCDOUBLED1,589,562$25.9M
Sculptor Capital LPNEW905,000$14.7M
MORGAN STANLEYTRIM616,142$10.0M
Jump Financial, LLCDOUBLED348,100$5.7M
MARSHALL WACE, LLPDOUBLED306,396$5.0M
HRT FINANCIAL LPNEAR_EXIT214,951$3.5M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

11 analysts
Buy 55% rate it Buy or better
Strong Buy3Buy3Hold5Sell0Strong Sell0
12-month targets · 3 analysts

Price is inside the target range. Median implies +10%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Oct 6, 2026BTIG
DOWNGRADE
DOWNGRADENeutral
Jul 20, 2026Lake Street
DOWNGRADE
DOWNGRADEHold
Jul 20, 2026BTIG
MAINTAIN
MAINTAINBuy
Jul 20, 2026Needham
DOWNGRADE
DOWNGRADEHold
Jul 17, 2026Needham
MAINTAIN
MAINTAINBuy
Jul 9, 2026Morgan Stanley
MAINTAIN
MAINTAINEqual-Weight

Insider ledger

Form 4
$0
bought · 0 insiders
$7.8M
sold · 4 insiders
DateInsiderTypeValue
Nov 3, 2026
Hall Christopher M
Chief Executive Officer
Nov 3, 2026
SELL$462.0K
Sep 18, 2026
Tachibana Aaron
CFO AND COO
Sep 18, 2026
SELL$47.5K
Sep 18, 2026
Hall Christopher M
Chief Executive Officer
Sep 18, 2026
SELL$121.0K
Sep 18, 2026
Chen Richard
President and CMO
Sep 18, 2026
SELL$64.8K
Sep 18, 2026
Moore Stephen Michael
SVP and Chief Legal Officer
Sep 18, 2026
SELL$33.5K
Jul 15, 2026
Chen Richard
President and CMO
Jul 15, 2026
EXERCISE$244.0K
Jul 15, 2026
Chen Richard
President and CMO
Jul 15, 2026
SELL$1.5M
Jul 9, 2026
Hall Christopher M
Chief Executive Officer
Jul 9, 2026
EXERCISE$161.0K

Earnings setup

Estimates
−$0.23
EPS estimate, this quarter
+2%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.23-$0.31–-$0.20+1.8%$25.2M
Next Q-$0.23-$0.25–-$0.22+0.0%$23.2M
Current FY-$1.16-$1.21–-$1.10-6.9%$88.7M
Next FY-$0.98-$1.18–-$0.84-4.5%$110.5M

Washington

Corporate Lobbying

10 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
6,747,693
shares short
-0.7%
vs prior settlement
3.3
days to cover
≈6.2%
of shares outstanding
Trading halts
Jul 20, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 13, 2026 SEC
ARK Investment Management and Catherine Wood filed Amendment No. 8 to Schedule 13G, reporting a 6.67% passive stake in…
SC 13G/A · Impact 2/10
Nov 12, 2026 SEC
Personalis filed an investor presentation urging stockholders to vote FOR the pending acquisition by Tempus AI at the…
425 · Impact 4/10
Nov 10, 2026 Earnings calendar
PSNL Q3 2026 Earnings Scheduled · 2026-11-10
Nov 3, 2026 Insider
Hall Christopher M sold 29,112 shares
Chief Executive Officer @ $15.87 ($462.0K)
Sep 30, 2026 Inst.
Aberdeen Group plc · ADD
5,211,939 shares ($148.6M)
Sep 30, 2026 Inst.
Qube Research & Technologies · DOUBLED
2,184,756 shares ($35.6M)
Sep 18, 2026 Insider
Tachibana Aaron sold 2,931 shares
CFO AND COO @ $16.22 ($47.5K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Nov 10, 2026
Earnings date
PSNL Q3 2026 Earnings Scheduled · 2026-11-10
Oct 27, 2026
Lobbying
PERSONALIS, INC. (PSNL) lobbies on a new issue: Medicare/Medicaid
First cited in Q3 2026, not in the four quarters before
Oct 27, 2026
Lobbying
PERSONALIS, INC. (PSNL) lobbies on a new issue: Pharmacy
First cited in Q3 2026, not in the four quarters before
Oct 27, 2026
Lobbying
PERSONALIS, INC. (PSNL) lobbying spend jumps: $100K in Q3 2026
+100% vs prior quarter, +43% vs a year earlier. Highest quarter on record. 2 firms
Oct 26, 2026
Lobbying
PERSONALIS, INC. (PSNL) hires lobbying firm TODD STRATEGY GROUP
Registration posted 2026-10-25

SecBot reports

29 filings · 6 bullish · 3 bearish · 20 neutral
All PSNL filing & press-release reports (29)